绿康生化2024年业绩巨亏 净资产转负触发双重风险警示

Core Viewpoint - Green Kang Biochemical Co., Ltd. faces significant financial distress, with a projected net asset value of -23 million yuan for 2024, marking the first negative net asset situation since its listing, alongside substantial expected losses in net profit [1][2][3] Financial Performance Summary - The revised performance forecast indicates a projected net profit loss of 43 million to 35 million yuan for 2024, with a net profit loss of 43.5 million to 38.5 million yuan after excluding non-recurring gains and losses [1] - This represents a deterioration compared to the previous year's net profit loss of 22.182 million yuan and a net profit loss of 23.078 million yuan after excluding non-recurring gains and losses [1] Risk Warning Summary - The company is at risk of being delisted due to two criteria: a projected negative net asset value and negative net profit for the last three consecutive years [2] - If the final audited net asset value is confirmed as negative, the company's stock will receive a delisting risk warning, marked with "*ST" [2] Business Transformation Challenges - The company's performance decline is closely linked to its business transformation efforts, including a failed acquisition in the pharmaceutical intermediate sector and challenges in the photovoltaic film market [3] - The competitive nature of the photovoltaic film market, along with price volatility of raw materials and integration issues with new assets, has led to significant asset impairment [3] Industry Insights - The case of Green Kang Biochemical highlights the potential risks associated with traditional manufacturing companies transitioning into emerging sectors, particularly in technology-intensive industries [3] - The need for substantial R&D investment and effective integration of cross-border acquisitions is emphasized, as failure to do so can lead to asset impairment and financial instability [3]